MYCN and neuroblastoma: Hsieh et al. conducted iTRAQ-labeled quantitative proteomics in the Th-MYCN mouse model (MYCN overexpressed hemizygous mice with spontaneous NB) and identified 150 significantly differential expressed proteins, following treatment with the aurora kinase inhibitor tozasertib [50].